Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MAT2A inhibitor in cancer cell lines

ABSTRACT: MAT2A inhibitor in cancer cell lines

PROVIDER: PRJNA679231 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13080173_1.fastq.gz	Fastqsanger.gz
	SRR13080173_2.fastq.gz	Fastqsanger.gz
	SRR13080174_1.fastq.gz	Fastqsanger.gz
	SRR13080174_2.fastq.gz	Fastqsanger.gz
	SRR13080175_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

MAT2A inhibitor in cancer cell lines

Project description:MAT2A inhibitor is dosed to MTAP null cell lines, samples are collected for transcriptome profiling

2020-12-09 | GSE161706 | GEO

Transcripitional profiling of Huh7 cells after MAT2A inhibitor (FIDAS-5) or BET bromodomain inhibitor (JQ1) treatment

Project description:RNA-seq analysis of Huh7 cells after MAT2A inhibitor (FIDAS-5) or BET bromodomain inhibitor (JQ1) treatment. The analysis revealed that inhibition of MAT2A or BET factors suppresses the expression of genes regulating cell cycle progression and additional cellular programs.

2022-02-28 | GSE184065 | GEO

Transcriptomic profile in in vitro produced bovine morulae treated with MAT2A inhibitor

Project description:We obtained transcriptomic profiles in bovine morulae which had been in vitro treated with a methionine adenosyltransferase 2A (MAT2A) inhibitor from the 8-16 cell stage.

2022-05-31 | GSE198294 | GEO

Transcriptional changes by PARP7 inhibitor in cancer cell lines

Project description:Transcriptional changes by PARP7 inhibitor in cancer cell lines

| PRJNA737116 | ENA

MAT2A as key regulator and therapeutic target in MLL leukemogenesis

Project description:Epigenetic dysregulation plays a pivotal role in MLL pathogenesis, therefore serving as suitable therapeutic point of attack. SAM is the universal methyl donor in human cells and is synthesized by MAT2A. MAT2A is already known to be deregulated in different cancer types. Here, we used our human CRISPR/Cas9-MLLr leukemia model, faithfully mimicking MLL patients’ pathology with indefinite growth potential in in vitro culture, to evaluate the unknown role of MAT2A as therapeutic target. Comparable to publicly available patient data, we detected MAT2A to be significantly overexpressed in our CRISPR/Cas9-MLLr model compared to healthy controls. By using non-MLLr and MLLr cell lines and our model, we detected an MLLr specific enhanced response to PF-9366, a new MAT2A inhibitor, by alteration of proliferation, viability, differentiation, apoptosis and cell cycling. Moreover, the combinational treatment of PF-9366 with chemotherapy or targeted therapies against the SAM-dependent methyltransferases DOT1L and PRMT5, revealed even more pronounced effects. In summary, we uncovered MAT2A as a key regulator in MLL leukemogenesis and its inhibition led to significant anti-leukemic effects. Therefore, our study paves the avenue for clinical application of PF-9366 to improve the treatment of poor prognosis MLLr leukemia.

2020-06-22 | GSE141839 | GEO

Transcriptome analysis of FAK inhibitor in liver cancer cell lines

Project description:Transcriptome analysis of FAK inhibitor in liver cancer cell lines

| PRJNA930966 | ENA

Genome-wide H3K27me3 profile in in vitro produced bovine morula treated with MAT2A inhibitor

Project description:We obtained genome-wide profiles of histone H3 lysine 27 trimethylation (H3K27me3) in bovine morula which had been in vitro treated with a methionine adenosyltransferase 2A (MAT2A) inhibitor from the 8-16 cell stage. Sequencing center: NODAI Genome Research Center, Tokyo University of Agriculture

2022-05-31 | GSE198293 | GEO

32 Kinase-Inhibitor Perturbed RNA sequencing of 11 cancer cell-lines

Project description:32 Kinase-Inhibitor Perturbed RNA sequencing of 11 cancer cell-lines

| PRJNA773420 | ENA

Vemurafenib, BRAF inhibitor, Resistance in BRAFV600E Positive Thyroid Cancer cell lines

Project description:Vemurafenib, BRAF inhibitor, Resistance in BRAFV600E Positive Thyroid Cancer cell lines

| PRJNA738167 | ENA

Human prostate cancer cell lines treated with BET Bromodomain inhibitor JQ1

Project description:Human prostate cancer cell lines treated with BET Bromodomain inhibitor JQ1

| PRJNA523251 | ENA